NEOGEN CORP is 1.3x more valuable than Anbio Biotechnology by market capitalization ($2.00 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NNNN | NEOG |
|---|---|---|
| Market cap | $1.50 B | $2.00 B |
| US-listed rank | #2315 | #2099 |
| Revenue (latest FY) | $8.65M | $894.66M |
| Net income (latest FY) | $6.40M | -$1.09B |
| Net margin | 74.1% | -122.1% |
| P/E (trailing FY) | 234.2 | - |
| SEC filings | 40 | 1,896 |
NEOGEN CORP is 1.3x more valuable than Anbio Biotechnology by market capitalization ($2.00 B vs $1.50 B).
In their latest fiscal years, Anbio Biotechnology reported $8.65M in revenue while NEOGEN CORP reported $894.66M.
Full pages: Anbio Biotechnology and NEOGEN CORP, or browse the full rankings.